Phase 4 N=34,758 Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil
Tuberculosis
Primary: Notification Rate Ratio — 48.7; 30.5 notifications/100,000 persons/year — p=<0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=75 An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
Schizophrenia
Primary: Change From Baseline in Personal and Social Performance (PSP) Scale Score at Week 52 — 50.65; 58.71; 5.35; 5.96 units on a scale — p=0.8595
Phase 4 N=13 FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
Autism Spectrum Disorder
Primary: Baseline and Week 8scores on Children's Yale-Brown Obsessive Compulsive Scale - Pervasive Developmental Disorder Version — 12.7; 8.6 Scores on a scale
Phase 4 N=27 A Randomised Cross-over Study With Two 1-piece Urostomy Bags.
Urostomy
Primary: Preference of Sensura vs Moderma — 45; 43 percentage of prefering the product
Phase 4 N=218 Daily Wear Corneal Infiltrative Event Study
Myopia · Hyperopia · Corneal Infiltrative Events
Primary: Number of Participants Developing a Corneal Inflammatory Event (CIE) — 6; 7 participants
Phase 4 N=400 Resistance Under the Microscope
Anxiety
Primary: Quality of Recovery Score — 172.8; 176.3; 174.5; 176.4 scores on a scale
Phase 4 N=60 A Comparison of Naropin and Ketorolac for Postoperative Analgesia After Total Knee Arthroplasty
Postoperative Pain
Primary: Morphine Consumption — 48.75; 10 mg
Phase 4 N=324 The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial
Relapsing Multiple Sclerosis
Primary: Percentage of Responders as Defined by Single Nucleotide Polymorphism (SNP) Markers — 63.5; 63.9; 65.6; 60.3 percentage of participants
Phase 4 N=736 A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects
Rheumatoid Arthritis
Primary: Response at Week 12 as Assessed by Randomized Tool [Clinical Disease Activity Index (CDAI) or Routine Assessment of Patient Index Data 3 (RAPID3)] — 64.7; 76.4; 35.3…
Phase 4 N=15 PR-018: An Open-Label, Safety Extension of Study PR-011
Cystic Fibrosis · Exocrine Pancreatic Insufficiency
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 15; 3; 10; 4 participants
Phase 4 N=29 Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
Ascites · Cirrhosis
Primary: Time to Recurrence of Ascites. — 10; 8 days — p=<0.05
Phase 4 N=49 A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501
Retraction of Colostomy
Primary: Total Opioid Burden — 67.7; 38.41 mg morphine equivalent
Phase 4 N=387 Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants
Schizophrenia
Primary: Change From Baseline in Symptom Checklist 90-R (SCL90-R) at Week 24 — 99.84; 73.03; 67.66; 13.09 Units on a scale
Phase 4 N=491 PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia
Schizophrenia
Primary: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on Clinical Global Impression-Improvement (CGI-I) Scale - Intent-to-treat (ITT)…
Phase 4 N=32 Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons
HSV Infection · HIV Infection
Primary: Mean Level of HIV-1 RNA in Plasma of Participants While on Acyclovir or Valacyclovir. — 3.56; 2.94 log10 copies/mL